fi ed. Fusion protein vectors were transfected into hepatocytes by liposomal transfection. AGT expression and subcellular distribution was monitored by GFP fl uorescence. Results: HepG2 cells express full-length mRNA coding for AGT as confi rmed by insert size as well as sequence determination. Selective primers allowed us to generate a modifi ed recombinant GFP-AGT fusion protein. Cellular transfections with Lipofectamine resulted in transfection effi ciencies of 60-90%. The recombinant AGT did localize to peroxisomes as monitored by GFP fl uorescence. Conclusions: The results demonstrate preliminary in vitro feasibility data for AGT transfection into the hepatocytes. To the best of our knowledge, this is the fi rst study to attempt recombinant AGT gene therapy for treatment of primary hyperoxaluria-1.
aminase (AGT). Detoxifi cation of glyoxalate is thus impaired and overproduction of oxalate ensues. The disease is characterized by increased urinary excretion of oxalate and glycolate. The urine oxalate excretion rate in affected patients is typically 3-to 6-fold increased compared to normal levels, leading to recurrent urolithiasis and nephrocalcinosis in childhood or adolescence. Loss of renal function due to hyperoxaluria leads to the accumulation of insoluble oxalate throughout the body, i.e. oxalosis. These changes result in organ system dysfunction including ischemic ulcers of the skin, metabolic bone disease, refractory anemia, cardiomyopathy, and cardiac conduction system abnormalities, resulting in severe morbidity and mortality. Historically, the median age at death was only 36 years [1] [2] [3] .
AGT (E.C. 2.6.1.44) is an intermediary metabolic enzyme that catalyses the transamination of glyoxalate to glycine using alanine as the amino donor [4] . AGT is a homodimeric protein, each subunit containing 392 amino acid residues with a molecular weight of 43 kDa [5] . Depending on the particular species, AGT in hepatocytes can be peroxisomal, mitochondrial or both peroxisomal and mitochondrial [6] . AGT is known to fulfi ll a gluconeogenic role in mitochondria and glyoxalate detoxifi cation in peroxisomes. Although some animal species have signifi cant levels of AGT in the cytosol, the metabolic role of this enzyme in the cytosol is unknown [6] .
A wide variety of enzymatic phenotypes have been identifi ed in PH-1, including loss of AGT catalytic activity due to inhibition of co-factor binding, loss of immunoreactive AGT protein due to accelerated degradation, intraperoxisomal AGT aggregation and a remarkable traffi cking defect found in about one third of patients in whom ϳ 90% of the AGT is mistargeted from its normal intracellular location in the peroxisomes to the mitochondria. The AGT enzyme is encoded by a single copy gene (AGXT) consisting of 11 exons, ranging from 65 to 407 bp and spanning a 10-kb DNA segment in the 2q37.3 human region. So far, seven polymorphisms and 40 mutations have been identifi ed in the AGXT gene [7] . The disease is caused by homozygous point mutations or by compound heterozygosity in two different point mutations. AGT mistargeting does not result from any direct interference with its peroxisomal targeting, which is achieved by an unusual non-consensus C-terminal type 1 peroxisomal targeting sequence (PTS 1) [8] . Mitochondrial targeting sequences are typically N-terminal positively charged amphiphilic ␣ -helices which are cleaved after import [9] . To date, treatment for PH-1 includes high fl uid intake supported by calcium oxalate crystallization inhibitors in combination with diuretics, oral administration of pyridoxal-5-phosphate (a co-factor of AGT); daily hemodialysis, or synchronous liver-kidney transplantation. It is impossible to establish uniform therapeutic guidelines as it requires individualized strategy and current treatments are not fully satisfactory.
Corrective gene therapy offers a potential approach to the treatment of genetic disorders in man. This is a technique whereby the absent or faulty gene is replaced by a working gene, so that the body can make the correct enzyme or protein and consequently eliminate the cause of the disease. An elegant approach to treat PH-1 would be to deliver a functionally active AGT gene to hepatocytes. However, a low effi ciency of gene delivery in vivo has prevented the widespread implementation of this technology in the clinic. Because of formidable obstacles in gene therapy, there are no ongoing trials of gene therapy either in the laboratory or in the clinical setting for PH-1. In the present study, we provide results from our feasibility studies with AGT transfections into hepatocytes with the long-term goal of developing a rational gene therapy for patients suffering from PH-1. 
Materials and Methods

Materials
Construction of the cDNA Library
Total RNA was isolated from HepG2 cells using an RNeasy kit (Qiagen). A cDNA library was generated with random primers using the iScript cDNA kit (BioRad) as described by the manufacturers of these kits.
Cloning of AGT
Primers were designed for the AGT sequence (Accession No. NM 000030) that would delete the N-terminal 38 residues of normal AGT, which forms a mitochondrial targeting sequence, and, in addition, insert a short amino acid sequence at the C-terminal end (Ser-Lys-Leu) to serve as a peroxisomal targeting sequence [10] .
The forward and reverse primers designed were as follows: AGT (F) primer: 5 -GCA TGA ATT CCA CCA TGG ACT ACA AGG ACG ACG ATG ACA AGA TGG CAG CCG GGG GGC TGC AG-3 , and AGT (R) primer: 5 -CAG TGT CGA CTC ACA GCT TGG ACA GCT TCT TCT TGG GGC AGT GC-3 .
The forward primer sequence contains clamp sequence to allow Eco RI cleavage, Eco RI cleavage site, Kozak ribosome binding site and FLAG-tag site besides priming sequence for AGT. Similarly, the reverse primer sequence contains Sal 1 cleavage site, and information for generating strong PTS1.
Generation of the GFP-FLAG-AGT Fusion Protein
To generate the GFP-FLAG-AGT fusion protein, AGT cDNA was ligated into the pEGFP-C1 vector (Clontech) as a ϳ 1.2 kb Eco R1-Sal 1 fragment, in which AGT was fused to the carboxy terminus of GFP ( fi g. 1 ), and transformed into TOP 10 cells. Selected kanamycin-resistant colonies were used for Mini-Preps to confi rm the insertion of the fusion sequence (Quantum Prep, BioRad). The integrity of the construct was verifi ed by DNA sequencing (DNA sequencing and analysis core, University of Colorado School of Medicine).
Cellular Transfections
HepG2 cells were transfected with Lipofectamine (Invitrogen) resulting in ϳ 60-90% transfection effi ciency. The GFP-FLAG-AGT fusion protein construct was effi ciently transfected to 293 T cells, a line of embryonic kidney cells as well as HepG2 cells. Expression was confi rmed through fl uorescence microscopy. Stable clones expressing the GFP-FLAG-AGT fusion protein were derived from HepG2 cells following selection with G418.
Results
Construction of cDNA Library
RNA isolated from HepG2 cells was analyzed for purity and stability before performing RT-PCR to synthesize cDNA. Amplifi cation of AGT-cDNA using the primers described above is shown in fi gure 2 .
Cloning of AGT
The product of RT-PCR was inserted into the EGFP-C1 vector as an Eco R1-Sal 1 fragment. Six kanamycinresistant TOP 10 colonies were processed for Mini-Prep plasmid isolation to confi rm the insertion, and out of 6 colonies selected, 5 of them showed positive insertion ( fi g. 3 ).
Cellular Transfections
Stable clones of HepG2 cells which expressed GFP-FLAG-AGT fusion protein were obtained by G418 selection of transfected cells. Among the selected clones, 4 clones expressed the fusion protein ( fi g. 4 ). These colonies were maintained for further studies and analysis.
Subcellular Localization of Fusion Protein
Cellular distribution of GFP-FLAG-AGT protein was observed and photographed at 400 nm under fl uorescence microscopy ( fi g. 5 A, B). Microscopic observation suggested that AGT fusion protein was correctly localized in the desired target peroxisomes of HepG2 cells.
Discussion
The classic approach to gene transfer for a genetic disease has been to use a vector to supply a normal copy of the defective gene. Such a treatment strategy was successfully used as a therapeutic approach for hemophilia using a transgene product of FVIIa [11] . In the present study, we cloned a functional AGT from hepatocytes and genetically engineered it for selective delivery to peroxisomes. We have also tagged the AGT with GFP for easy visualization and for the purpose of obtaining proof of our principles.
AGT primarily has two metabolic roles: glyoxalate detoxifi cation in peroxisomes and gluconeogenesis in mitochondria. The use of the term 'ineffi cient' in a targeting context might be considered to be rather pejorative, but targeting ineffi ciency could be an advantage for the cell and could have evolved as a way of localizing an enzyme to more than one compartment, particularly when compartments are in the cytosol. Many mechanisms are involved in order to localize similar metabolic reactions or other cellular processes to more than one part of the cell including gene duplication, alternative transcription, translation initiation and alternative splicing. Ineffi cient or incomplete targeting can be added to this mechanism [6] .
It has been shown previously that the C-terminal tripeptide of human AGT is necessary for peroxisomal import [6] . There is evidence suggesting that the natural Cterminal tripeptide of AGT is not as effi cient as the consensus PTS 1 at directing the peroxisomal import of AGT. Although the appropriate topogenic information is present in polymorphic AGT to target it to mitochondria, it might be prevented from doing so by the rapidity with which the protein adopts a conformation incompatible with the mitochondrial import machinery. In most normal individuals, AGT is localized exclusively in the peroxisomes of liver parenchymal cells (hepatocytes), but in about one third of patients, ϳ 90% of the AGT is mistargeted to mitochondria [12] . Although AGT remains catalytically active after import into the mitochondria, it is metabolically ineffective due to the fact that the peroxisome, not the mitochondrion, is the major site of synthesis of glyoxalate. Hence, one goal of the study was to eliminate mistargeting. To achieve these objectives, the Nterminal sequence containing mitochondrial targeting information was eliminated and the primers designed started from the 2nd methionine residue. By deleting Nterminal sequences targeting mitochondrial import we expected the protein to adopt a conformation which is incompatible with mitochondrial import. Unlike the peroxisomal import machinery which appears to be able to import fully folded oligomeric proteins without breaking them apart, the mitochondrial import machinery can only cope with unfolded or loosely folded monomers [8, [13] [14] [15] [16] [17] [18] [19] . In addition, we inserted a strong peroxisomal targeting sequence (PTS 1) coded by three amino acids SerLys-Leu into the C-terminal end to ensure peroxisomal targeting during gene delivery. Clearly the results presented in fi gure 4 A-C suggest that most GFP-AGT was localized to peroxisomes. Our study promises a new and novel approach for delivering the AGT gene into peroxisomes, thereby ensuing complete glyoxalate detoxifi cation -an outcome very necessary for patients suffering the inherited metabolic disorder PH-1.
In summary, our preliminary data demonstrate that HepG2 cells express AGT mRNA. We also show that the recombinant GFP-AGT fusion protein can be effi ciently transfected into hepatocytes in vitro , by liposome-mediated gene delivery approaches. Moreover, the modifi ed recombinant AGT can be targeted to peroxisomes. These encouraging in vitro feasibility studies support the notion that corrective gene therapy for PH-1 could become a reality. However, additional data are necessary to demonstrate the feasibility of our approaches in vivo in preclinical models. Currently, adenoviral vector systems have been approved for human gene therapy. These vector systems offer high transfection effi ciency and dose, and the amount of gene to be delivered can be tightly controlled. We have undertaken generation of adenoviral vector system/s as possible in vivo AGT delivery vehicles. These recombinant-AGT-adenoviral systems could offer a new therapeutic approach for the treatment of PH-1.
